Information Provided By: 
Fly News Breaks for August 3, 2017
HOLX
Aug 3, 2017 | 07:57 EDT
Goldman analyst Isaac Ro removed Hologic from the Conviction Buy List saying Q3 results were disappointing and the product cycle/balance sheet flexibility thesis has played out. Ro said the Q3 report raised new questions about the strategic rationale of the Cynosure transaction, future M&A strategy, and the company's organic growth rate. The analyst maintains a Buy rating and $47 price target on shares but said it will need to deliver consecutive earnings beat and a clearer path to sustained MSD organic growth before the multiple improves.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
